Clinical Trials Logo

Plasmacytosis clinical trials

View clinical trials related to Plasmacytosis.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01301807 Completed - Clinical trials for Recurrent Plasma Cell Myeloma

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Start date: July 28, 2011
Phase: Phase 1
Study type: Interventional

This phase I/Ib trial studies the side effects and best dose of panobinostat and carfilzomib in treating participants with multiple myeloma that has come back or that isn't responding to treatment. Carfilzomib keeps cancer cells from repairing themselves. If the cancer cells cannot repair themselves, they may die. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving panobinostat and carfilzomib may work better in treating participants with multiple myeloma.